Cargando…
Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?
Currently, drug repurposing is an alternative to novel drug development for the treatment of COVID-19 patients. The antimalarial drug chloroquine (CQ) and its metabolite hydroxychloroquine (HCQ) are currently being tested in several clinical studies as potential candidates to limit SARS-CoV-2-mediat...
Autores principales: | Derwand, R., Scholz, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202847/ https://www.ncbi.nlm.nih.gov/pubmed/32408070 http://dx.doi.org/10.1016/j.mehy.2020.109815 |
Ejemplares similares
-
COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study
por: Derwand, Roland, et al.
Publicado: (2020) -
The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review
por: Das, Subham, et al.
Publicado: (2021) -
Molecular docking identification for the efficacy of some zinc complexes with chloroquine and hydroxychloroquine against main protease of COVID-19
por: Hussein, R.K., et al.
Publicado: (2021) -
The battle against perioperative glycaemic control: Hard to win?
por: Parthasarathy, S., et al.
Publicado: (2022) -
Winning the battle of refractory hypotony
por: Maheshwari, Devendra, et al.
Publicado: (2022)